Clarus Therapeutics Holdings (CRXT) Financials

$0.02

$-0.01 (-19.54%)

As on 08-Nov-2022 09:30EDT

Market cap

$2 Mln

Revenue (TTM)

$19 Mln

P/E Ratio

--

P/B Ratio

0

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-13	Dec-12	Dec-11	Dec-10	Dec-09	Dec-08	Dec-07
Operating Revenue	19.24	13.96	6.37	--	--	--
Cost of Revenue	3.99	2.72	8.69	--	--	--
Gross Profit	15.25	11.24	-2.32	--	--	--
Operating Expenses	65.94	50.97	2.98	--	--	--
Operating Profit (EBIT)	-39.90	-39.73	-47.18	--	--	--
Other Income	10.11	--	--	--	--	--
Profit before Tax	-48.07	-40.62	4.35	--	--	--
Provision for Tax	--	--	--	--	--	--
Profit after Tax (Net Income)	-48.07	-40.62	4.35	--	--	--
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-32.22	-40.21	-10.34	-55.24	-30.27	-22.53

Liabilities ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-13	Dec-12	Dec-11	Dec-10	Dec-09	Dec-08	Dec-07
Shareholder's Funds	-13.06	-15.92	40.34	--	--	--
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.20	1.57	18.71	--	--	--
Current Liabilities	61.81	66.06	0.42	77.07	4.18	3.86
Total Liabilities	110.75	51.71	59.47	--	--	--

Assets ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-13	Dec-12	Dec-11	Dec-10	Dec-09	Dec-08	Dec-07
Non-Current Assets	0.06	0.07	58.65	--	--	--
Current Assets	48.88	51.64	0.82	9.85	0.26	5.30
Total Assets	110.75	51.71	59.47	--	--	--
Total Debt*	40.51	42.27	--	--	--	--
Net Current Assets	-12.93	-14.42	-40.48	--	--	--

Cashflow ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-13	Dec-12	Dec-11	Dec-10	Dec-09	Dec-08	Dec-07
Cash From Operating Activities	--	-43.79	-41.58	-19.72	-21.79	-15.62
Cash Flow from Investing Activities	--	-0.03	-0.06	-0.02	-0.02	-0.02
Cash from Financing Activities	--	62.99	47.22	18.36	18.88	-2.70
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-13	Dec-12	Dec-11	Dec-10	Dec-09	Dec-08	Dec-07
Adjusted EPS ($)	--	--	--	--	--	--
Cash EPS ($)	--	--	--	--	--	--
Adjusted Book Value ($)	--	--	--	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	--	--	--	--	--
Free Cash Flow per Share ($)	--	--	--	--	--	--

Profitability Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-13	Dec-12	Dec-11	Dec-10	Dec-09	Dec-08	Dec-07
ROCE (%)	--	-121.81	21.54	--	--	--
ROE (%)	--	-332.62	10.77	--	--	--
ROA (%)	-44.53	-73.06	7.31	--	--	--
EBIT Margin (%)	-171.85	-177.13	-740.73	--	--	--
Net Margin (%)	-163.77	-291.02	68.22	--	--	--
Cash Profit Margin (%)	-0.01	--	--	--	--	--

Growth Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-13	Dec-12	Dec-11	Dec-10	Dec-09	Dec-08	Dec-07
Revenue Growth (%)	--	1.19	--	--	--	--
EBIT Growth (%)	--	47.60	-163.91	--	-44.75	--
Net Profit Growth (%)	--	-1,034.80	--	--	--	--
EPS Growth (%)	--	--	--	--	--	--
Book Value Growth (%)	--	--	--	--	--	--

Valuation Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-13	Dec-12	Dec-11	Dec-10	Dec-09	Dec-08	Dec-07
Price / Earnings	--	--	--	--	--	--
Price / Book Value	--	--	--	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-1.04	-0.64	--	--	--	--
Close Price ($)	0.38	2.43	--	--	--	--
High Price ($)	10.57	10.57	--	--	--	--
Low Price ($)	0.33	2.35	--	--	--	--
Market Cap ($ Cr)	2.47	--	--	--	--	--

Solvency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-13	Dec-12	Dec-11	Dec-10	Dec-09	Dec-08	Dec-07
Debt to Equity	--	-2.66	--	--	--	--
Short term debt to equity ratio	-3.10	-2.66	--	--	--	--
Current Ratio	0.79	0.78	1.96	0.13	0.06	1.37
Quick Ratio	0.52	0.57	-11.96	0.04	--	--
Interest Coverage	-2.20	-1.56	-3.06	--	--	--

Operating Efficiency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-13	Dec-12	Dec-11	Dec-10	Dec-09	Dec-08	Dec-07
Debtors to sales (%)	45.25	45.43	69.08	--	--	--
Asset Turnover	0.18	0.25	0.11	--	--	--
Receivable days	--	140.54	252.33	--	--	--
Inventory Days	--	1,347.60	269.47	--	--	--
Payable days	--	948.28	95.81	--	--	--
Cash Conversion Cycle	--	539.86	425.99	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.